Suppr超能文献

核蛋白 mRNA 经皮内给药为小鼠提供针对流感的交叉株免疫。

Intranodal administration of mRNA encoding nucleoprotein provides cross-strain immunity against influenza in mice.

机构信息

Laboratory for Molecular and Cellular Therapy, Department of Biomedical Sciences, Vrije Universiteit Brussel (VUB), Jette, Belgium.

VIB-UGent Center for Medical Biotechnology, VIB, Ghent, Belgium.

出版信息

J Transl Med. 2019 Jul 25;17(1):242. doi: 10.1186/s12967-019-1991-3.

Abstract

BACKGROUND

Current human influenza vaccines lack the adaptability to match the mutational rate of the virus and therefore require annual revisions. Because of extensive manufacturing times and the possibility that antigenic alterations occur during viral vaccine strain production, an inherent risk exists for antigenic mismatch between the new influenza vaccine and circulating viruses. Targeting more conserved antigens such as nucleoprotein (NP) could provide a more sustainable vaccination strategy by inducing long term and heterosubtypic protection against influenza. We previously demonstrated that intranodal mRNA injection can induce potent antigen-specific T-cell responses. In this study, we investigated whether intranodal administration of mRNA encoding NP can induce T-cell responses capable of protecting against a heterologous influenza virus challenge.

METHODS

BALB/c mice were immunized in the inguinal lymph nodes with different vaccination regimens of mRNA encoding NP. Immune responses were compared with NP DNA vaccination via IFN-γ ELISPOT and in vivo cytotoxicity. For survival experiments, mice were prime-boost vaccinated with 17 µg NP mRNA and infected with 1LD50 of H1N1 influenza virus 8 weeks after boost. Weight was monitored and viral titers, cytokines and immune cell populations in the bronchoalveolar lavage, and IFN-γ responses in the spleen were analyzed.

RESULTS

Our results demonstrate that NP mRNA induces superior systemic T-cell responses against NP compared to classical DNA vaccination. These responses were sustained for several weeks even at low vaccine doses. Upon challenge infection, vaccination with NP mRNA resulted in reduced lung viral titers and improved recovery from infection. Finally, we show that vaccination with NP mRNA affects the immune response in infected lungs by lowering immune cell infiltration while increasing the fraction of T cells, monocytes and MHC II alveolar macrophages within immune infiltrates. This change was associated with altered levels of both pro- and anti-inflammatory cytokines.

CONCLUSIONS

These findings suggest that intranodal vaccination with NP mRNA induces cross-strain immunity against influenza, but also highlight a paradox of influenza immunity, whereby robust immune responses can provide protection, but can also transiently exacerbate symptoms during infection.

摘要

背景

目前的人类流感疫苗缺乏适应病毒突变率的能力,因此需要每年修订。由于广泛的制造时间和抗原性改变发生在病毒疫苗株生产过程中的可能性,新流感疫苗与流行病毒之间存在抗原不匹配的固有风险。针对核蛋白(NP)等更保守的抗原进行靶向治疗可能通过诱导针对流感的长期和异源保护提供更可持续的疫苗接种策略。我们之前证明,淋巴结内 mRNA 注射可以诱导有效的抗原特异性 T 细胞反应。在这项研究中,我们研究了 NP 编码 mRNA 的淋巴结内给药是否可以诱导能够抵抗异源流感病毒挑战的 T 细胞反应。

方法

BALB/c 小鼠通过腹股沟淋巴结用不同的 NP 编码 mRNA 疫苗方案进行免疫。通过 IFN-γ ELISPOT 和体内细胞毒性比较免疫反应与 NP DNA 疫苗。对于生存实验,小鼠用 17µg NP mRNA 进行初免-加强免疫,并在加强免疫后 8 周用 1LD50 的 H1N1 流感病毒感染。监测体重和支气管肺泡灌洗液中的病毒滴度、细胞因子和免疫细胞群以及脾中的 IFN-γ 反应。

结果

我们的结果表明,NP mRNA 诱导针对 NP 的全身性 T 细胞反应优于经典的 DNA 疫苗。即使在低疫苗剂量下,这些反应也能持续数周。在挑战感染时,NP mRNA 接种导致肺部病毒滴度降低,感染恢复改善。最后,我们表明,NP mRNA 接种通过降低免疫细胞浸润而增加浸润免疫细胞中的 T 细胞、单核细胞和 MHC II 肺泡巨噬细胞的比例来影响感染肺部的免疫反应。这种变化与促炎和抗炎细胞因子的水平改变有关。

结论

这些发现表明,NP mRNA 淋巴结内接种可诱导针对流感的交叉株免疫,但也突出了流感免疫的一个悖论,即强大的免疫反应可以提供保护,但也可以在感染期间暂时加重症状。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8aee/6659201/24d4610b1a2a/12967_2019_1991_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验